US2017073409A1PendingUtilityA1

Il-17a/f heterologous polypeptides and therapeutic uses thereof

Assignee: GENENTECH INCPriority: Jul 8, 2003Filed: May 20, 2015Published: Mar 16, 2017
Est. expiryJul 8, 2023(expired)· nominal 20-yr term from priority
A61P 37/06A61P 9/00A61P 37/02A61P 37/00A61P 37/08A61P 7/06A61P 7/00A61P 3/10A61P 5/00A61P 31/18A61P 25/02A61P 33/00A61P 31/04A61P 31/22A61P 29/00A61P 25/00A61P 27/16A61P 31/10A61P 31/20A61P 31/12A61P 31/16A61P 17/00A61P 19/02A61P 19/00A61P 13/12A61P 11/02A61P 21/00A61P 11/00A61P 17/06A61P 1/04A61P 17/04A61P 1/00A61P 1/16A61P 11/06C07K 2317/34C07K 2317/21C07K 16/244A61K 38/00C07K 2317/75C07K 2317/32C07K 2317/565C07K 2317/24C07K 14/54C07K 2317/76G01N 33/6869C07K 2317/55C07K 2317/622C12N 15/11C07K 16/00A61K 38/17G01N 2800/24G01N 2500/10C07K 2319/40C07K 2319/30C07K 2317/92C07K 2317/33C07K 2317/31A61K 2039/505A61K 38/2073Y02A50/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Claims

exact text as granted — not AI-modified
1 - 55 . (canceled) 
     
     
         56 : A method of treating an IL-17A/F-associated immune related inflammatory disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an antibody that binds to an IL-17A/F polypeptide complex consisting of the polypeptide of SEQ ID NO:3 and the polypeptide of SEQ ID NO:4 with or without their signal peptides. 
     
     
         57 : The method of  claim 56 , wherein the immune related disorder is systemic lupus erythematosis, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an idiopathic inflammatory myopathy, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, a demyelinating disease of the central or peripheral nervous system, idiopathic demyelinating polyneuropathy, Guillain-Barré syndrome, a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary disease, infectious or autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's disease, an autoimmune or immune-mediated skin disease, a bullous skin disease, erythema multiforme, contact dermatitis, psoriasis, an allergic disease, asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity, urticaria, an immunologic disease of the lung, eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, a transplantation associated disease, graft rejection or graft-versus-host-disease. 
     
     
         58 - 75 . (canceled)

Join the waitlist — get patent alerts

Track US2017073409A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.